Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Current Deferred Revenue (2016 - 2026)

OptimizeRx's Current Deferred Revenue history spans 16 years, with the latest figure at $503000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 6.34% to $503000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $503000.0, a 6.34% increase, with the full-year FY2025 number at $503000.0, up 6.34% from a year prior.
  • Current Deferred Revenue hit $503000.0 in Q4 2025 for OptimizeRx, up from $395000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for OPRX hit a ceiling of $1.4 million in Q4 2021 and a floor of $164000.0 in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $616661.9 across 5 years, with a median of $493500.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: soared 386.33% in 2021 and later tumbled 88.2% in 2022.
  • Tracing OPRX's Current Deferred Revenue over 5 years: stood at $1.4 million in 2021, then tumbled by 88.2% to $164000.0 in 2022, then grew by 4.88% to $172000.0 in 2023, then surged by 175.0% to $473000.0 in 2024, then increased by 6.34% to $503000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for OPRX at $503000.0 in Q4 2025, $395000.0 in Q3 2025, and $484000.0 in Q2 2025.